In addition, the lesions are typically distributed symmetrically on the scalp, elbows ... The various types and presentations of psoriasis are outlined below. The commonest form of psoriasis is plaque ...

The approval was supported by data from 2 randomized, double-blind, vehicle-controlled trials that included 736 patients aged 12 years and older with mild to severe plaque psoriasis of the scalp and ...

Topical roflumilast 0.3% cream has been approved by the FDA to treat plaque psoriasis in patients 12 years and older since ...

Arcutis Biotherapeutics has received FDA approval for ZORYVE (roflumilast) topical foam 0.3%, which is now available for treating plaque psoriasis on the scalp and body in patients aged 12 and older.

The 0.3% foam formulation of roflumilast was previously approved for the treatment of seborrheic dermatitis in adults and ...

The U.S. Food and Drug Administration (FDA) has approved ZORYVE® (roflumilast) topical foam 0.3% for the treatment of plaque psoriasis of the scalp and body in adults and children aged 12 and ...

Nearly 9 million people in the United States are living with plaque psoriasis, with over half having scalp involvement and even more presenting with the disease in other hair-bearing areas.